Levotiroksin Tedavisi Alan Ötiroid Hashimoto Hastalarında Tiroid Dışı Kanserler: Tek Bir Tersiyer Merkezin Hastalarına Bakış

Yıl 2025, Cilt: 47 Sayı: 1, 39 - 48, 17.01.2025

Havva Sezer

https://doi.org/10.20515/otd.1562220

Öz

Levotiroksin (LT4) tedavisi alan ötiroid Hashimoto hastalarında tiroid dışı kanser (TDK) sıklığını araştırmayı amaçladık. Ayrıca kanser gelişiminin demografik, klinik, biyokimyasal ve metabolik parametrelerle ilişkili olup olmadığını da belirledik. Aralık 2016 ile Aralık 2023 tarihleri arasında tek bir tersiyer merkezde Hashimoto tiroiditi (HT) kaynaklı hipotiroidi tanısı alan 18 yaş üzeri takipteki ardışık katılımcılar çalışmaya dahil edildi. Toplam 577 Hashimoto hastası retrospektif olarak analiz edildi. Çalışma popülasyonu TDK olup olmamasına göre iki alt gruba ayrıldı. Kanserli ve kansersiz hastalarda demografik, klinik, biyokimyasal ve metabolik parametreler karşılaştırıldı.Bulgular: Ortalama yaş 52,6±13,5 yıldı. Beş yüz yetmiş yedi hastanın %87,3'ü kadın, %12,7'si erkekti. HT’ne eşlik eden en sık iki komorbidite metabolik sendrom (%36,4) ve obezite (%31,2) idi. HT ile TDK’in birlikte görülme sıklığı %13,3 idi. En sık görülen iki kanser meme (%46,2) ve over (%8,7) oldu. Çok değişkenli analizde, ileri yaşın (OR 1,030, %95 CI 1,012-1,049, p=0,001), pozitif aile öyküsünün (OR 1,859, %95 CI 1,117-3,092, p=0,017) ve yüksek açlık kan şekerinin (OR) 1,022, %95 CI 1,007-1,037, p=0,005) artan kanser riski ile anlamlı pozitif korelasyona sahip olduğu bulunmuştur. Bu çalışma, LT4 tedavisi alan ötiroid Hashimoto hastalarında TDK sıklığının %13,3 olduğunu ortaya çıkardı. Meme kanseri, çalışma popülasyonunu etkileyen en yaygın kanserdi. İleri yaş, pozitif aile öyküsü ve yüksek açlık kan şekeri, kanser gelişimi için bağımsız risk faktörleri olarak tanımlandı.

Anahtar Kelimeler

Hashimoto tiroiditi, hipotiroidi, tiroid dışı kanserler

Extra-thyroidal Cancers in Euthyroid Hashimoto’s Patients Under Levothyroxine Treatment: Outlook A Single Tertiary Center Cases

Öz

We aimed to investigate the frequency of extra-thyroidal cancer (ETC) in euthyroid Hashimoto’s patients under levothyroxine (LT4) treatment. Moreover, we determined whether cancer development could be related to demographic, clinical, biochemical, and metabolic parameters. Consecutive participants in the follow-up above 18 years old diagnosed with hypothyroidism caused by Hashimoto’s thyroiditis (HT) in a single tertiary center between 2016 December and 2023 December were included in the study. A total of 577 Hashimoto’s patients were analyzed retrospectively. The study population was divided into two subgroups according to presence or absence of ETC. Demographic, clinical, biochemical, and metabolic parameters were compared in patients with and without cancer. Mean age was 52.6±13.5 years. Of the 577 patients, 87.3% were female and 12.7% were male. The most prevalent two comorbidities accompanying HT were metabolic syndrome (36.4%) and obesity (31.2%). The frequency of concomitant appearance of ETC with HT was 13.3%. The most common two cancers were breast (46.2%) and ovary (8.7%). In multivariate analysis, older age (OR 1.030, 95% CI 1.012-1.049, p=0.001), positive family history for cancer (OR 1.859, 95% CI 1.117-3.092, p=0.017), and elevated fasting blood glucose (OR 1.022, 95% CI 1.007-1.037, p=0.005) were found to be significantly positively correlated with increased risk of cancer. This study revealed that the frequency of ETC was 13.3% in euthyroid Hashimoto’s patients under LT4 treatment. Breast cancer was the most common cancer affecting study population. Older age, positive family history for cancer and elevated fasting blood glucose were defined as independent risk factors for cancer development.

Anahtar Kelimeler

Hashimoto’s thyroiditis, hypothyroidism, extra-thyroidal cancers

Kaynakça

• 1. Malhab LJB, Saber-Ayad MM, Al-Hakm R, Nair VA, Paliogiannis P, Pintus G, et al. Chronic inflammation, and cancer: the role of endothelial dysfunction and vascular inflammation. Curr Pharm Des. 2021;27(18):2156-69.
• 2. Hu X, Wang X, Liang Y, Chen X, Zhou S, Fei W, et al. Cancer risk in Hashimoto’s thyroiditis: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:937871.
• 3. Khandia R, Munjal A. Interplay between inflammation and cancer. Adv Protein Chem Struct Biol. 2020;119:199-245.
• 4. Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017;16(10):1049-57.
• 5. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation. J Clin Endocrinol Metab. 2013;98(2):474-482.
• 6. Lai X, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget. 2017;8(37):62414-62424.
• 7. Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol. 2006;154(5):645-9.
• 8. Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50.
• 9. Rokavec M, Öner MG, Hermeking H. Inflammation-induced epigenetic switches in cancer. Cell Mol Life Sci. 2016;73(1):23-39.
• 10. Fröhlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol. 2017;8:521.
• 11. Haapala AM, Hyöty H, Parkkonen P, Mustonen C, Soppi E. Antibody reactivity against thyroid peroxidase and myeloperoxidase in autoimmune thyroidits and systemic vasculitis. Scand J Immunol. 1997;46(1):78-85.
• 12. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodine transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6(8):871-8.
• 13. Davies TF. The thyrotrophin receptors spread themselves around. J Clin Endocrinol Metabol. 1994;79(5):1232-3.
• 14. Rojas A, Schneider I, Lindner C, Gonzalez I, Morales MA. Association between diabetes and cancer. Current mechanistic insights into the association and future challenges. Mol Cell Biochem. 2023;478(8):1743-58.
• 15. Hu Y, Zhang X, Ma Y, Yuan C, Wang M, Wu K, et al. Incident type 2 diabetes duration and cancer risk: a prospective study in two US cohorts. J Natl Cancer Inst. 2021;113(4):381-9.
• 16. Zádori N, Szakó L, Váncsa S, Vörhendi N, Oštarijaš E, Kiss S, et al. Six autoimmune disorders are associated with increased incidence of gastric cancer: a systematic review and meta-analysis of half a million patients. Front Immunol. 2021;12:750533.
• 17. Gontarz-Nowak K, Szklarz M, Szychlińska M, Matuszewski W, Bandurska-Stankiewicz E. A brief look at Hashimoto’s disease, adrenal incidentalomas, obesity, and insulin resistance-could endocrine disruptors be the other side of the same coin? Medicina (Kaunas). 2023;59(7):1234.
• 18. Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. J Mol Med (Berl). 2021;99(9):1175-93.
• 19. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman CI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and prevention: National Heart, Lung, and Blood Institute; American heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
• 20. Yang Y, Liu J, Shi X, Wang M. Clinical and pathological characteristics of patients with papillary thyroid carcinoma coexisting with Hashimoto’s thyroiditis: a retrospective cohort study. Cancer Control. 2023;30:10732748231199647.
• 21. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133(3):1169-77.
• 22. Chen YK, Lin CL, Cheng FT, Sung FC, Kao CH. Cancer risk in patients with Hashimoto’s thyroiditis: a nationwide cohort study. Br J Cancer. 2013;109(9):2496-2501.
• 23. Chiappa C, Rovera F, Rausei S, Del Ferraro S, Fachinetti A, Lavazza M, et al. Breast cancer and thyroid diseases: analysis of 867 consecutive cases. J Endocrinol Invest. 2017;40(2):179-184.
• 24. Sarlis NJ, Gourgiotis L, Pucino F, Tolis GJ. Lack of association between Hashimoto thyroiditis and breast cancer: a quantitative research synthesis. Hormones (Athens). 2002;1(1):35-41.
• 25. Prinzi N, Sorrenti S, Baldini E, De Vito C, Tuccilli C, Catania A, et al. Association of thyroid diseases with primary extra-thyroidal malignancies in women: results of a cross-sectional study of 6,386 patients. PLoS One. 2015;10(3):e0122958.
• 26. Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J. Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence. Semin Cancer Biol. 2020;64:114-121.
• 27. Till M, Rapson N, Smith PG. Family studies in acute leukemia in childhood: a possible association with autoimmune disease. Br J Cancer. 1979;40(1):62-71.
• 28. Graceffa G, Scerrino G, Militello G, Laise I, Randisi B, Melfa G, et al. Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor? Futur Sci OA. 2021;7(5):FSO699.
• 29. Shi XZ, Jin X, Xu P, Shen HM. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(16):6643-7.
• 30. Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson OB, Malm C, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies relation to breast cancer risk. Int J Cancer. 2012;131(9):2126-33.
• 31. Silva JM, Domínguez G, González-Sancho JM, García CM, Silva J, García-Andrade C, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002;21(27):4307-16.
• 32. Moskowitz C, Dutcher JP, Wiernik PH. Association of thyroid disease with acute leukemia. Am J Hematol. 1992;39(2):102-7.
• 33. Huang CH, Wei CJ, Chien TC, Kuo CW, Lin SH, Su YC, et al. Risk of breast cancer in females with hypothyroidism: a nationwide, population-based, cohort study. Endocr Pract. 2021;27(4):298-305.
• 34. Wang B, Lu Z, Huang Y, Li R, Lin T. Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis. BMC Cancer. 2020;20(1):733.
• 35. Leung JH, Wang SY, Leung HW, Yu TS, Chan ALF. Hypothyroidism and hyperthyroidism related to gynecologic cancers: a nationwide population-based cohort study. Sci Rep. 2024;14(1):1892.
• 36. Rostkowska O, Spychalski P, Dobrzycka M, Wilczyński M, Łachiński AJ, Obołończyk Ł, et al. Effects of thyroid hormone imbalance on colorectal cancer carcinogenesis and risk- a systematic review. Endokrynol Pol. 2019;70(2):190-7.
• 37. Dore MP, Manca A, Alfonso Pensamiento MC, Delitala AP, Fanciulli G, Piana AF, et al. Male predominance of gastric cancer among patients with hypothyroidism from a defined geographic area. J Clin Med. 2020;9(1):135.
• 38. Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JO, Dekkers OM, Sørensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016;174(4):409-14.
• 39. L’Heureux A, Wieland DR, Weng CH, Chen YH, Lin CH, Lin TH, et al. Association between thyroid disorders and colorectal cancer risk in adult patients in Taiwan. JAMA Netw Open. 2019;2(5):e193755.
• 40. Liu W, Zhi FH, Zheng SY, Yang HS, Geng XJ, Luo HH, et al. Hypothyroidism reduces the risk of lung cancer through oxidative stress response and PI3K/Akt signaling pathway: an RNA-seq and Mendelian randomization study. Heliyon. 2023;9(12):e22661.
• 41. Mondul AM, Weinstein SJ, Bosworth T, Remaley AT, Virtamo J, Albanes D. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One. 2012;7(10):e47730.
• 42. Lu L, Wan B, Li L, Sun M. Hypothyroidism has a protective causal association with hepatocellular carcinoma: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13:987401.
• 43. Weng CH, Okawa ER, Roberts MB, Park SK, Umbricht CB, Manson JE, et al. Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the women’s health initiative. Thyroid. 2020;30(4):519-30.
• 44. Boursi B, Haynes K, Mamtani R, Yang YX. Thyroid dysfunction, thyroid hormone replacement and colorectal cancer risk. J Natl Cancer Inst. 2015;107(6):djv084.
• 45. Wang B, Luo Y, Liu T, Xu S, Pei J, Liu J, et al. Assessment of bidirectional relationships between hypothyroidism and endometrial cancer: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024;15:1308208.
• 46. Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I, et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing, and Body Composition Study. Endocrinol. 2012;76(6):911-8.
• 47. Park HK, Ahima RS. Endocrine disorders associated with obesity. Best Pract Res Clin Obstet Gynaecol. 2023;90:102394.
• 48. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al, International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer-viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794-8.
• 49. Liu W, Chakraborty B, Safi R, Kazmin D, Chang CY, McDonnell DP. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat Commun. 2021;12(1):5103.